SUWANEE, GA, Oct. 31, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) and Premier Shockwave, Inc. are pleased to announce that Premier Shockwave will exhibit at the Desert Foot Annual Multi-Disciplinary Limb Salvage Conference at the Sheraton Grand Phoenix in Phoenix, AZ, November 7 - 10, 2018 at booth #61. Premier Shockwave is SANUWAVE Health, Inc.’s exclusive distributor to the Veterans Administration (VA), the Indian Health Service (IHS) and the Tribally operated healthcare services market.
“We are looking forward to exhibiting and demonstrating SANUWAVE’s dermaPACE® System at the Desert Foot Annual Multi-Disciplinary Limb Salvage Conference annual meeting,” stated Mike Stolarski, CEO & President of Premier Shockwave Wound Care, Inc. an affiliate of Premier Shockwave, Inc. According to the organizers, the Desert Foot 15th Annual Multi-Disciplinary Limb Salvage Conference is THE educational event of the year for podiatrists and other healthcare specialties interested in preservation of the lower extremity.
Premier Shockwave is using this occasion to formally introduce SANUWAVE’s lead wound care product, the dermaPACE® System. Premier Shockwave is the exclusive provider of the dermaPACE® System to the VA and IHS. This Focused Electro-Hydraulic Extracorporeal Shockwave Technology (FEHEST) device has been proven to be safe and effective in the treatment of Diabetic Foot Ulcers in two US based clinical trials. The dermaPACE® exhibited superiority in wound area reduction from baseline as compared to Standard of Care beginning at 6 weeks from initial treatment and superiority in wound closure at 20 weeks from initial treatment and out through 24 weeks. The use of the dermaPACE® System allows the clinician to more easily, and more cost-effectively, manage wounds. More importantly, the patient’s quality of life improves significantly.
If you are interested in scheduling a meeting with the team, please contact David Anderson via e-mail at david@premiershockwave.com; otherwise, please stop by booth #61.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
About Premier Shockwave, Inc. and Premier Shockwave Wound Care, Inc.
Premier Shockwave, Inc. is the leading shockwave company for podiatric and orthopedic applications using OssaTron® and dermaPACE® devices throughout the United States and currently serves over 30 VA Hospitals and Military Treatment Facilities in the continental United States and Alaska. Premier Shockwave, Inc. will manage the dermaPACE® business for Premier Shockwave Wound Care, Inc. For additional information about the company, please go to www.premiershockwave.com.
About Desert Foot Annual Multi-Disciplinary Limb Salvage Conference
The Desert Foot 15th Annual Multi-Disciplinary Limb Salvage Conference is the educational event of the year for podiatrists and other healthcare specialties interested in preservation of the lower extremity. Taking place at the Sheraton Grand Phoenix November 7-10, this 4-day event brings together lower extremity professionals from seven groups: Veterans Administration (VA), Department of Defense, Public Health Services, Indian Health Service, VA Podiatric Residency Directors, the Arizona Podiatric Medical Association, and those from the Private Sector. Originally an event exclusively for podiatrists practicing in the Federal Health Service, it has grown into a huge multi-disciplinary event focused on high-risk conditions of the lower extremities. The Conference places top national speakers at the podium during the comprehensive state-of-the-art general sessions which cover evidence-based and best practices for utilizing the latest surgical procedures, advanced wound care technologies, vascular interventions, amnio/cellular therapy, biomechanics, off-loading, compression therapy techniques, dermatology of the lower limb and new techniques in the management of foot disorders. Desert Foot 2018 will also include the PRESENT signature rotating hands-on workshop program, where each day includes a series of six workshops where participants receive individual personalized instruction on the latest surgical procedures, advanced wound care technologies and other patient-focused clinical skills that they can employ in their practices on Monday morning. www.desertfoot.org
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.